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of the efﬁcacy of the
procedure.Based upon earlier experience with surgical sympathectomy and considerable data inexperimental animals, clinical studies began to evaluate whether transcatheter renalsympathetic denervation (RDN) by radiofrequency ablation could provide effective
therapy for resistant hypertension. The initial reports were glowing, multiple (largely un-
controlled) publications ensued, the procedure received the European CE mark approval,
and the European Society of Cardiology released a consensus statement that catheter-based
renal denervation could be considered a therapeutic option in patients with drug-resistant
hypertension. By 2013, it was estimated that approximately 10,000 patients had been treated
with RDN throughout the world (1). Perhaps the ultimate barometer of the enthusiasm
with which the scientiﬁc and industrial medical community viewed renal denervation was
that Medtronic Inc. (Minneapolis, Minnesota) paid $800 million up front to purchase
Ardian (Mountain View, California), the company that had developed the technology.
To that point, the evidence supporting the therapeutic efﬁcacy of RDN for resistant
hypertension was based largely upon the SYMPLICITY HTN-2 (Renal Sympathetic
Denervation in Patients With Treatment-Resistant Hypertension) trial (2), which was the
only prospective controlled study conducted. Concerns were expressed even with respect
to SYMPLICITY HTN-2 in regard to the lack of blinding and long-term follow-up, the
potentially suboptimal administration of and adherence to medical therapy, and the failure
to do ambulatory blood pressure monitoring. A meta-analysis published in 2013 found
294 papers dealing with renal denervation, virtually all of which yielded positive results;
however, only 18 of these, consisting of 561 patients, satisﬁed their entry criteria. Never-
theless, the enthusiasm for the procedure was almost boundless, and there was speculation
about the use of RDN for moderate hypertension and even in patients who did not want to
take antihypertensive drugs. It remained only for the completion of SYMPLICITY HTN-3
(3), a protocol in which patients were blinded by performing a sham procedure, to obtain
Food and Drug Administration approval and enable the procedure to diffuse into clinical
practice.
As is now well known, to the utter amazement of nearly everyone, the SYMPLICITY
HTN-3 trial failed to show a beneﬁt of RDN over optimal medical therapy (4). Possible ex-
planations include the introduction of the placebo effect, tightening of medical therapy, the
application of ambulatory pressure monitoring, and even the lack of expertise of new in-
vestigators. The exact reasons for the unexpected results remain to be deﬁned.Nevertheless, the
most surprising aspect tomewas the fact that the SYMPLICITYHTN-3 trial yielded negative
results despite the impressive body of published data that provided evidence of the efﬁcacy of
the procedure. How could so many investigators doing somany independent protocols with so
many different endpoints bewrong?How could somany editors and reviewers choose to accept
so many papers that would ultimately appear to be misleading?
I want to acknowledge upfront that the Journal played a signiﬁcant role in the dissemi-
nation of data that attested to the efﬁcacy of RDN. We published a meta-analysis and an
expert consensus statement, as well as 8 research papers on renal denervation, some with
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1453editorials (5–14). Although cautionary of limited early re-
sults, all articles reached a favorable conclusion on the pro-
cedure, and the original research papers provided evidence of
therapeutic beneﬁt. Many of the original research papers
reported not only reductions of blood pressure, but also end
organ beneﬁts such as decreases in vascular stiffness, left
ventricular hypertrophy, and recurrences of atrial ﬁbrillation.
All were subjected to rigorous peer-review, and were judged
to be in a high-priority category for publication by the ed-
itors at our weekly meetings. In aggregate, they seemed to
provide a ﬁrm scientiﬁc basis for the belief that RDN would
be an effective therapy, and this was a sense that was
certainly conveyed to our readers.
In reﬂecting on the discrepancy between the data that
we published and the results of the SYMPLICITY HTN-3
trial, several thoughts to mind. As JACC editors, we tend to
place a very high importance on novelty in deciding whether
to accept or reject a submitted manuscript. Our criteria are
sometimes abbreviated as “new, true, and relevant.” I assume
this is true of all journals; everyone wants to be the ﬁrst to
publish original information, and we ﬁnd conﬁrmatory data
less appealing. Therefore, a new procedure, particularly one
for which very promising early results exist, is likely to
receive an extra boost when assigning priority for acceptance.
In addition, a novel, rapidly emerging technology will
stimulate a great deal of research and result in multiple
publications and citations, all of which can affect the hateful,
imperfect, but yet critically inﬂuential impact factor. Taken
together, these considerations may help to explain how
studies that have relatively small sample sizes, no or limited
controls, and less than absolutely perfect methodology ach-
ieve such prominence in the medical literature.
The ultimate fate of renal denervation therapy for resis-
tant hypertension remains unknown. Factors responsible for
the negative results of the SYMPLICITY HTN-3 trial may
be identiﬁed and rectiﬁed in future studies. Alternate tech-
niques that are more effective at achieving sympathetic renal
denervation may be developed. It is certainly not my
intention to presume the death knell of the approach.
However, it is well to consider that investigational results
that are surprisingly good and lacking full understanding of
the physiological mechanism of beneﬁt should be viewed
with caution. This is particularly true when the studies
supporting beneﬁt are of limited size, and not prospective,
randomized, controlled, blinded trials. We should be wary of
authors who are overly enthusiastic about their ﬁndings, and
we must recognize the subconscious bias that may inﬂuenceeditors when selecting manuscripts for publication. The
SYMPLICITY HTN-3 trial provided critically important
information in regard to transcatheter renal denervation, but
what it said about our process of developing and evaluating
new technology was perhaps even more important.
Address correspondence to:
Dr. Anthony N. DeMaria
Editor-in-Chief, Journal of the American College of Cardiology
3655 Nobel Drive, Suite 630
San Diego, California 92112
E-mail: ademaria@acc.org
REFERENCES
1. Kandzari DE, Sobotka PA. Ready for a marathon, not a sprint: renal
denervation therapy for treatment-resistant hypertension. J Am Coll
Cardiol 2013;62:2131–3.
2. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE,
Böhm M, for the Symplicity HTN-2 Investigators. Renal sympathetic
denervation in patients with treatment-resistant hypertension (The
Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;
376:1903–9.
3. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal
denervation for resistant hypertension: rationale and design of the
SYMPLICITY HTN-3 Trial. Clin Cardiol 2012;35:528–35.
4. Medtronic. Medtronic announces U.S. renal denervation pivotal trial
fails to meet primary efﬁcacy endpoint while meeting primary safety
endpoint. Available at: http://newsroom.medtronic.com/phoenix.
zhtml?c¼251324&p¼irol-newsArticle&ID¼1889335&highlight¼.
Accessed March 10, 2014.
5. Geisler BP, Egan BM, Cohen JT, et al. Cost-effectiveness and clinical
effectiveness of catheter-based renal denervation for resistant hyper-
tension. J Am Coll Cardiol 2012;60:1271–7.
6. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation
reduces left ventricular hypertrophy and improves cardiac function in
patients with resistant hypertension. J Am Coll Cardiol 2012;59:901–9.
7. Davis MI, Filion KB, Zhang D, et al. Effectiveness of renal denerva-
tion therapy for resistant hypertension. J Am Coll Cardiol 2013;62:
231–41.
8. Ott C, Mahfoud F, Schmid A, et al. Renal denervation in moderate
treatment-resistant hypertension. J Am Coll Cardiol 2013;62:1880–6.
9. Pokushalov E, Romanov A, Corbucci G, et al. A randomized com-
parison of pulmonary vein isolation with versus with without
concomitant renal artery denervation in patients with refractory
symptomatic atrial ﬁbrillation and resistant hypertension. J Am Coll
Cardiol 2012;60:1163–70.
10. Jin Y, Persu A, Staessen JA. Renal denervation in the management of
resistant hypertension. Curr Opin Nephrol Hypertens 2013;22:511–8.
11. Brandt MC, Reda S, Mahfoud F, Lenski M, Bohm M, Hoppe UC.
Effects of renal sympathetic denervation on arterial stiffness and central
hemodynamics in patients with resistant hypertension. J Am Coll
Cardiol 2012;60:1956–65.
12. O’Riordan M. SYMPLICITY THN-3 Complicates Renal-Denervation
Field, Say Experts. Heartwire, January 10, 2014.
13. Schlaich MP, Schmieder RE, Bakris G, et al. International Expert
Consensus Statement. J Am Coll Cardiol 2013;62:2031–45.
14. Zuern CZ, Eick C, Rizas KD, et al. Impaired cardiac baroreﬂex
sensitivity predicts response to renal sympathetic denervation in
patients with resistant hypertension. J Am Coll Cardiol 2013;62:
2124–30.
